Landscape Capital Management L.L.C. Acquires New Holdings in Masimo Co. (NASDAQ:MASI)

Landscape Capital Management L.L.C. bought a new stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 5,586 shares of the medical equipment provider's stock, valued at approximately $923,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Jones Financial Companies Lllp purchased a new position in shares of Masimo during the fourth quarter valued at about $27,000. UMB Bank n.a. grew its holdings in Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock valued at $32,000 after buying an additional 123 shares in the last quarter. Blue Trust Inc. increased its stake in Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock worth $33,000 after acquiring an additional 71 shares during the last quarter. Trust Co. of Vermont purchased a new stake in shares of Masimo during the 4th quarter worth approximately $33,000. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Masimo by 40.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 64 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Trading Up 1.6 %

MASI stock traded up $2.41 during mid-day trading on Friday, reaching $153.90. 729,386 shares of the stock traded hands, compared to its average volume of 655,434. The business has a 50-day moving average price of $170.60 and a two-hundred day moving average price of $164.27. The stock has a market capitalization of $8.32 billion, a PE ratio of 106.14 and a beta of 1.28. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo Co. has a one year low of $101.61 and a one year high of $194.88.

Remove Ads

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million for the quarter, compared to the consensus estimate of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Equities research analysts expect that Masimo Co. will post 4.1 EPS for the current year.

Insider Buying and Selling

In related news, Director Craig B. Reynolds sold 2,053 shares of the firm's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of Masimo stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the sale, the chief operating officer now owns 24,172 shares of the company's stock, valued at $4,048,568.28. The trade was a 55.38 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on MASI shares. Piper Sandler boosted their price target on shares of Masimo from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Raymond James boosted their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a report on Friday, December 27th. Needham & Company LLC reaffirmed a "hold" rating on shares of Masimo in a report on Thursday. Finally, Wells Fargo & Company lifted their price target on Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $194.80.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.